Formidable Asset Management LLC maintained its stake in shares of BioScrip, Inc. (NASDAQ:BIOS) during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 95,225 shares of the company’s stock at the end of the 2nd quarter. Formidable Asset Management LLC owned 0.08% of BioScrip worth $259,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently modified their holdings of BIOS. Teachers Advisors LLC lifted its holdings in shares of BioScrip by 14.0% during the fourth quarter. Teachers Advisors LLC now owns 162,778 shares of the company’s stock worth $169,000 after purchasing an additional 20,000 shares during the period. Wells Fargo & Company MN lifted its holdings in shares of BioScrip by 1.1% during the first quarter. Wells Fargo & Company MN now owns 113,710 shares of the company’s stock worth $193,000 after purchasing an additional 1,254 shares during the period. Bank of New York Mellon Corp lifted its holdings in shares of BioScrip by 7.6% during the first quarter. Bank of New York Mellon Corp now owns 475,844 shares of the company’s stock worth $809,000 after purchasing an additional 33,453 shares during the period. Alambic Investment Management L.P. acquired a new stake in shares of BioScrip during the first quarter worth $160,000. Finally, American International Group Inc. lifted its holdings in shares of BioScrip by 73.8% during the first quarter. American International Group Inc. now owns 67,812 shares of the company’s stock worth $115,000 after purchasing an additional 28,787 shares during the period. 84.15% of the stock is owned by hedge funds and other institutional investors.

In other news, Director Coliseum Capital Management, L sold 886,478 shares of the company’s stock in a transaction on Thursday, August 17th. The stock was sold at an average price of $3.08, for a total value of $2,730,352.24. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.80% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Formidable Asset Management LLC Has $259,000 Stake in BioScrip, Inc. (BIOS)” was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this story on another domain, it was stolen and republished in violation of international copyright and trademark legislation. The legal version of this story can be viewed at https://www.thecerbatgem.com/2017/09/16/formidable-asset-management-llc-has-259000-stake-in-bioscrip-inc-bios.html.

BioScrip, Inc. (BIOS) traded up 0.38% on Friday, reaching $2.67. The company’s stock had a trading volume of 1,336,195 shares. BioScrip, Inc. has a 52-week low of $0.98 and a 52-week high of $3.43. The firm has a 50-day moving average price of $2.87 and a 200 day moving average price of $2.26. The firm’s market capitalization is $340.36 million.

BioScrip (NASDAQ:BIOS) last announced its quarterly earnings data on Tuesday, August 8th. The company reported ($0.11) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.10) by ($0.01). The firm had revenue of $218.11 million during the quarter, compared to analyst estimates of $220.05 million. The firm’s revenue for the quarter was down 6.2% on a year-over-year basis. During the same period last year, the business posted ($0.14) EPS. Equities analysts anticipate that BioScrip, Inc. will post ($0.55) earnings per share for the current fiscal year.

Several equities research analysts recently weighed in on BIOS shares. Barrington Research increased their price target on BioScrip to $3.50 and gave the stock an “outperform” rating in a report on Monday, June 26th. Zacks Investment Research raised BioScrip from a “sell” rating to a “hold” rating in a report on Wednesday, June 28th. ValuEngine raised BioScrip from a “sell” rating to a “hold” rating in a report on Thursday, July 13th. BidaskClub downgraded BioScrip from a “strong-buy” rating to a “buy” rating in a report on Tuesday, August 1st. Finally, Jefferies Group LLC reiterated a “buy” rating and issued a $4.00 price objective (up previously from $3.00) on shares of BioScrip in a research report on Thursday, August 10th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the stock. BioScrip has a consensus rating of “Hold” and a consensus price target of $3.75.

BioScrip Profile

BioScrip, Inc is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment.

Institutional Ownership by Quarter for BioScrip (NASDAQ:BIOS)

Receive News & Stock Ratings for BioScrip Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip Inc. and related stocks with our FREE daily email newsletter.